Navigation Links
ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
Date:9/10/2010

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced that Michael McKelvey will be retiring from his positions as President and Chief Executive Officer and a director of ERT.  The Company's Board of Directors has begun a search for a successor.  Dr. McKelvey will continue in his current position until a successor is appointed or earlier, based on mutual agreement of Dr. McKelvey and the Board.

"I am honored to have led ERT for more than four years," commented Dr. McKelvey. "The acquisition of CareFusion Research Services and the emerging opportunities in healthcare represent a fundamental strategic shift in our business. The Company has transformed into a multi-product and service provider.  We have built a strong, well-diversified company that is very well positioned for growth in the future.  After over four years at the helm and at the age of 58, I feel the time is right to retire from this marvelous Company, focus on other interests, and devote more time to my family.  I leave ERT in a strong financial position, with a well diversified portfolio of products and services focused in cardiac safety, respiratory, multi-mode ePRO, and medical devices that can serve the research, pharmaceutical safety, and healthcare markets, a well thought out strategic vision and focus, and an excellent group of senior executives who individually and as a group are outstanding. We have achieved this due largely to the support of our employees, customers, the Board, and investors, and I would like to take this opportunity to thank them."  

Commenting on behalf of the Board of Directors, ERT's Chairman, Joel Morganroth, MD, said, "The Board accepts Mike's decision to retire with understanding and gratitude.  Mike leaves our Company positioned for future growth in the clinical research, pharmaceutical marketing, and healthcare markets.  The Board appreciates Mike's commitment to a successful transition while it conducts its search for a successor and wishes him the very best. The Company has retained Heidrick and Struggles, one of the nation's leading executive search firms, to assist in its search and will consider both internal and external candidates."

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development.  It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  ERT also provides solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as providing selected medical devices for the clinical trials and healthcare industries.  

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "will," "will continue" and other words and terms of similar meaning in conjunction with a discussion of future events.  These statements are subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in the forward-looking statements. Factors that might cause such a difference include unanticipated delays in recruiting a suitable successor for Dr. McKelvey or changes in Dr. McKelvey's ability or willingness to continue to serve during this transition process.

Forward-looking statements speak only as of the date made.  We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sysmex America Announces LabCorp Hematology Automation Agreement
2. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
3. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
4. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
5. Misonix Announces New Distribution Agreement For Spain
6. Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
7. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
8. ResMed Inc. Announces Completion of Two-for-One Stock Split
9. Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
10. Halozyme Therapeutics Announces Public Offering of Common Stock
11. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical ... heart failure, today announced that it intends to offer shares ... an underwritten public offering.  The offering is subject to market ... to whether or when the offering may be completed, or ...   --> --> Roth ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):